SGMO

Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on transforming patient lives through the development of genomic medicines. The company leverages advanced platform technologies including gene therapy, cell therapy, genome editing, and genome regulation to achieve its objectives. A cornerstone of Sangamo's approach is its proprietary zinc finger protein (ZFP) technology platform. This platform facilitates the creation of zinc finger nucleases, which are specialized proteins capable of precisely altering DNA sequences by either inserting or inactivating specific genes. Furthermore, it produces ZFP transcription factors, proteins designed to modulate (increase or decrease) gene expression. Sangamo has a robust clinical pipeline, with key programs progressing through various stages. SB-525 is currently in the Phase III AFFINE clinical trial for the treatment of hemophilia A. Their gene therapy candidate, ST-920, is undergoing Phase I/II STAAR clinical trials for Fabry disease, while the cell therapy SAR445136 is being evaluated in Phase I/II PRECIZN-1 clinical trials for sickle cell disease. The company's development efforts also extend to other therapeutic areas, including TX200, a chimeric antigen receptor for addressing HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy targeting cancer; ST-501 for tauopathies; and ST-502, which is aimed at treating synucleinopathies like Parkinson's disease and other neuromuscular disorders. Sangamo has established numerous collaborative and strategic partnerships with leading entities such as Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and the California Institute for Regenerative Medicine. Established in 1995, the company was initially known as Sangamo BioSciences, Inc. It subsequently adopted its current name, Sangamo Therapeutics, Inc., in January 2017. The corporate headquarters are situated in Brisbane, California.